Comparing clopidogrel vs cilostazol for diabetes-related artery thickening
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial compares two blood-thinning drugs (clopidogrel and cilostazol) to see which one better prevents artery problems in people with diabetes and thickened carotid arteries. It may help you if you have diabetes and are already on stable medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 or older and have diabetes
- A carotid artery ultrasound shows some thickening (1.0 mm or more) in the artery wall
- You have been on the same diabetes, blood pressure, and cholesterol medicines for at least 3 months
- You are not currently taking blood thinners (other than aspirin) and have no bleeding problems
- You have not had a stroke, heart attack, or heart procedure in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking cilostazol and aspirin together can help prevent heart attacks, strokes, and other cardiovascular events in people with type 2 diabetes who have early signs of artery disease or metabolic syndrome. It aims to see if this combination is more effective than aspirin alone.
This trial tests whether taking just one blood thinner (clopidogrel) is as safe and effective as taking two (clopidogrel plus aspirin) for older adults or people at high bleeding risk who have had a drug-coated balloon procedure to open blocked heart arteries.
This trial tests two blood-thinning medications (sarpogrelate and clopidogrel) to see which one improves blood flow in the legs better and is safer for people who have had a stroke and also have leg pain when walking due to narrowed arteries.
This trial compares two common “blood thinner” combinations to prevent problems after a PCI procedure for complex blocked heart arteries. It may help your care team find which combination works better for people with higher-risk artery patterns.
This study compares two blood-thinning medicines—ticagrelor and clopidogrel—after you’ve already had a drug-eluting stent placed for a heart attack. It aims to see which option better prevents new heart-related events in people at higher risk.
This trial tests whether tailoring anti-platelet (blood clot prevention) treatment can better protect people at higher risk of heart or blood-vessel problems after a drug-eluting stent. It may help prevent future clots and complications, especially in patients with certain high-risk health conditions or complex stent/scar tissue features.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.